Serious adverse drug reactions with sacubitril/valsartan Entresto®: a French pharmacovigilance survey
Notes
Compliance with ethical standards
Conflicts of interest
The authors declare that they have no conflict of interest.
Disclaimer
The content of this article only involved the authors and the opinions and conclusions are not necessary those of ANSM (Agence Nationale de Sécurité du Médicament et des produits de santé). Authors of this article are solely responsible for the conclusions.
References
- 1.McMurray JJV, PackeR M, DesaI AS, Jianjian Gong J, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Solomon SD, Swedberg K, Zile MR, For the PARADIGM-HF investigators and committees (2014) Angiotensin–neprilysin inhibition versus enalapril in heart failure. N Engl J Med 371:993–1004CrossRefPubMedGoogle Scholar
- 2.Vial T (2016) French pharmacovigilance: missions, organization and perspectives. Therapie 71:143–150CrossRefPubMedGoogle Scholar
- 3.Miremont-Salamé G, Théophile H, Haramburu F, Bégaud B (2016) Causality assessment in pharmacovigilance: the French method and its successive updates. Therapie 71:179–186CrossRefPubMedGoogle Scholar
- 4.European Medicine Agency. Entresto Summary of Product Characteristics. www.ema.europa.eu/docs. Accessed 13 Feb 2018
- 5.Patel N, Gluck J (2017) Is Entresto good for the brain? World J Cardiol 9:594–599CrossRefPubMedPubMedCentralGoogle Scholar
Copyright information
© Springer-Verlag GmbH Germany, part of Springer Nature 2018